You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 10, October 1999 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (8)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Psoriasis
 •Phototherapy
 •Alert me on articles by topic

Lack of Consensus Among Experts on the Choice of UV Therapy for Psoriasis

Robert S. Stern, MD; Janusz Z. Beer, MD; DeEtta K. Mills

Arch Dermatol. 1999;135:1187-1192.

Context  Each year tens of thousands of patients in the United States are treated with UV-B radiation or psoralen plus UV-A radiation (PUVA) for a variety of skin disorders. Although PUVA is generally considered more effective, it is also more toxic and more expensive. The degree of consensus among experts in prescribing these alternative treatments has not been quantified.

Objectives  To quantify variation among specialty clinics in the type of ultraviolet therapy used to treat specific skin conditions and assess factors associated with the use of specific treatments.

Design  Survey conducted during two 2-week periods in the late fall of 1994 and early spring of 1995.

Setting  Thirty-nine specialty clinics in 17 US geographic areas in 14 states and Washington, DC.

Participants  A total of 3401 patients treated with UV radiation one or more times.

Outcome Measures  Type of UV therapy used and indications for treatment, age, sex, number of patients treated, and geographic location of each clinic.

Results  The proportion of patients at each center treated with PUVA ranged from 0% to 93% (mean, 41%). Clinic size and geographic location, demographic characteristics of the patients, and diagnosis did not explain these large intercenter differences.

Conclusions  Among specialized clinics, there is little consistency in the use of alternative therapies, which differ substantially in safety and cost, but whose relative efficacy is not well quantified. There is a lack of consensus among experts about the circumstances in which the greater risks and costs of PUVA are outweighed by its possibly greater efficacy, especially in the treatment of psoriasis.


From Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (Dr Stern); and the Center for Devices and Radiological Health, Food and Drug Administration, Rockville, Md (Dr Beer and Ms Mills).


RELATED ARTICLE

Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 1999;135(10):1282-1283.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey
Krueger et al.
Arch Dermatol 2001;137:280-284.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.